Multiple case reports have shown some clinical efficacy of BRAF inhibitors (vemurafenib, dabrafenib) either alone or in combination with MEK inhibitors (trametinib) in BRAF-mutated glioma patients [4]. Here, BRAF is linked to central nervous system cancer.